AestheticsFeatured Articles

Increased Trend of Cosmetic Procedures in Patients With Psoriasis Who Attain 75% or Greater Improvement

By August 25, 2020No Comments

Featured Article

Featured Article

A survey was conducted at a single dermatology center to determine if there was an increased trend in cosmetic procedures in patients with moderate to severe psoriasis who attained 75% or greater reduction of the body surface area (BSA) with biologic agents and oral systemic therapies, and if this was related to an improvement in quality of life following psoriasis clearance.

Read more

A survey was conducted at a single dermatology center to determine if there was an increased trend in cosmetic procedures in patients with moderate to severe psoriasis who attained 75% or greater reduction of the body surface area (BSA) with biologic agents and oral systemic therapies, and if this was related to an improvement in quality of life following psoriasis clearance.

Michelle E. Walters MD, Delphine J. Lee MD PhD, Paul S. Yamauchi MD PhD

Psoriasis is a chronic skin condition with a negative impact on patient quality of life. The National Psoriasis Foundation states that an acceptable response to psoriasis treatment is at least a 75% reduction in body surface area (BSA) at 3 months after initiation of treatment.

This reduction in BSA has been associated with improvement in quality of life, with clearance rates of clear to almost clear leading to an even greater improvement in quality of life.2,3 To date, there have been no studies examining the relationship between improvement in quality of life following a reduction in BSA, and the increased utilization of cosmetic procedures. Here, we examine the relationship between quality of life and the use of various cosmetic procedures in patients treated for psoriasis with systemic and biologic therapies who achieved at least 75% reduction in BSA.

This was a retrospective study assessing quality of life and the use of cosmetic procedures in psoriasis patients after attaining a75% or greater reduction of the body surface area with biologic agents only, systemic agents only, or a combination of both. This study was conducted according to the ethical guidelines of the 1975 Declaration of Helsinki. All patients provided informed consent.

Read Full Article Now
Article Cited in this Post

You May Also Like

Touching on Tailored Topical for Tons of Tough Treatment Tchallenges

| Featured Articles, Featured Podcast, Podcast Highlights, The Latest | No Comments
Featured Podcast Even in a world of exponentially expanding systemic options both on and off label, one fact remains: topical therapy is ALWAYS on the menu. With an unprecedented array…
Journal of Drugs in Dermatology JDD About Spesolimab for the Treatment of Generalized Pustular Psoriasis Flares

Spesolimab for the Treatment of Generalized Pustular Psoriasis Flares

| Featured Articles, Latest News, Psoriasis, The Latest | No Comments
Did you miss this March article? Generalized pustular psoriasis (GPP) is a serious and unpredictable skin condition with limited treatment options. The Effisayil 1 trial evaluated spesolimab, a monoclonal antibody…
Journal of Drugs in Dermatology JDD About Latin America Cutaneous Oncology Management (LACOM) I: The Role of Skin Care in Oncology Patients and Survivors

Latin America Cutaneous Oncology Management (LACOM) I: The Role of Skin Care in Oncology Patients and Survivors

| Featured Articles, Latest News, Oncodermatology, The Latest | No Comments
Prioritizing Skincare in Cancer Treatment: A Latin American Initiative Cancer treatments often lead to skin-related side effects that impact quality of life and, in some cases, treatment adherence. The Latin…

Leave a Reply